NurExone Biologic

08/09/2026

25/08/2026

Sign up here!

Register for the webinar: https://small-microcap.eu/event/webinar-from-a-cutting-edge-research-trend-to-a-multi-billion-market-the-investment-potential-of-exosomes/

September 1st at 5:00 PM CEST | 11:00 AM EDT

29/07/2026

We are pleased to welcome David Stolick to NurExone's Board of Directors.

David succeeds the late James Richardson, whose lasting contributions helped shape NurExone during its formative years.

Read the full announcement: https://www.globenewswire.com/news-release/2026/07/28/3334841/0/en/corporate-updates-nurexone-appoints-mr-david-stolick-to-the-board-of-directors.html

25/06/2026

Exo-Top, NurExone’s wholly owned U.S. subsidiary, entered into a binding MOU with ExoLyra for the distribution of naïve MSC-derived exosome products in Mexico.

The agreement marks Exo-Top’s first structured commercial entry and supports NurExone’s dual-track strategy: near-term exosome commercialization alongside continued ExoPTEN therapeutic development.

Read More: https://www.globenewswire.com/news-release/2026/06/24/3317189/0/en/exo-top-nurexone-s-wholly-owned-u-s-subsidiary-enters-into-binding-mou-for-na%c3%afve-exosome-distribution-in-mexico.html

Learn more about Exo-Top: https://nurexone.com/exo-top/

15/06/2026

Geekonomy pairs two ideas that are deeply connected: “geek” and “economy,” reflecting how scientific curiosity, technical depth, and entrepreneurship help drive economic growth.

In this episode of the Geekonomy podcast, Lior Shaltiel, PhD joins Reem Sherman to discuss one of medicine’s most complex challenges: central nervous system injuries, including spinal cord injury and optic nerve damage, and NurExone’s work with exosome-based regenerative medicine.

Many thanks for hosting us.

Listen and enjoy (Hebrew):

ד״ר ליאור שאלתיאל הוא מנכ״ל חברת נוראקסון, שמטפלת באחד האתגרים המורכבים ביותר של עולם הרפואה: פגיעה במערכת העצבים המרכזית, כמו פגיעות בחוט השדרה או בעצב הראיה, באמצע...

01/06/2026

We announced our Q1 2026 financial results and corporate update.

Highlights include:

✅ Technion proteomic analysis supporting our regulatory roadmap

✅ Exo-Top sublicense supporting the Company’s U.S. strategy

✅ BioXtek LOI for potential U.S. exosome manufacturing and commercialization

✅ ExoPTEN and platform IP progress in Australia and Korea

✅ Completion of a March private placement strengthening the Company’s balance sheet and supporting strategic initiatives

Read the full announcement: https://www.globenewswire.com/news-release/2026/06/01/3304336/0/en/nurexone-announces-first-quarter-2026-financial-results-and-provides-corporate-update.html

28/04/2026

Australia has granted NurExone a patent covering the production of extracellular vesicles from stem cells, further expanding the Company’s international patent family around exosome biomanufacturing.

This follows previously announced patents in Israel and the United States, with additional applications under examination in other jurisdictions.

As NurExone advances its manufacturing capabilities and clinical-readiness strategy, expanding IP protection across key markets is another step in building long-term value.

🔗 Read more: https://www.globenewswire.com/news-release/2026/04/27/3281998/0/en/australian-patent-granted-to-nurexone-covering-stem-cell-derived-exosome-production.html

07/04/2026

This is a really important milestone for NurExone....

Today’s strategic (non-binding) LOI between our U.S. subsidiary, Exo-Top, and BioXtek marks an important step on two critical fronts: therapeutic advancement and commercial readiness.

On the therapeutic side, the planned collaboration is expected to support U.S. GMP manufacturing and clinical supply of naïve MSC exosomes, an important building block for the future clinical development of ExoPTEN.

On the commercial side, it could open new opportunities for broader exosome manufacturing and supply in the U.S. and beyond, combining Exo-Top’s proprietary Master Cell Bank and exosome production know-how with BioXtek’s established Florida-based GMP infrastructure.

This is a meaningful step forward in building the capabilities needed to support both clinical progress and commercial opportunity.

Excited to move ahead together.
Read more: https://www.globenewswire.com/news-release/2026/04/07/3269290/0/en/NurExone-Biologic-s-U-S-Subsidiary-Exo-Top-and-Florida-Based-BioXtek-Sign-Strategic-LOI-for-Exosome-Manufacturing-and-Commercialization.html

06/04/2026

Why did someone with experience at the highest levels of healthcare, government, and finance choose to join NurExone’s board?

A recent profile of Eyal Gabbai by Gali Weinreb in Globes offers some insight!

Gabbai, currently Chairman of Meuhedet Health Services and formerly Director General of the Prime Minister’s Office and Director of the Government Companies Authority, described NurExone co-founder Yoram Drucker as “an optimistic person, but one who does not let optimism blind him,” calling that “a rare combination among entrepreneurs.” On NurExone’s work in spinal cord injury, he added that based on the Company’s animal studies, “it seems this is not a dream. It is very hard to say no to something like that.”

Read the full (Hebrew) article here: .https://www.globes.co.il/news/article.aspx?did=1001538632